No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HUMA240517P5000
- 0.05
- -0.05-50.00%
15min DelayTrading May 14 11:32 ET
0.08High0.05Low
0.05Open0.10Pre Close93 Volume444 Open Interest5.00Strike Price472.00Turnover205.59%IV-24.77%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.0781Delta0.1117Gamma131.60Leverage Ratio-0.0254Theta-0.0001Rho-10.27Eff Leverage0.0009Vega
Intraday
- 5D
- 1D
News
Individual Investors Who Own 53% Along With Institutions Invested in Humacyte, Inc. (NASDAQ:HUMA) Saw Increase in Their Holdings Value Last Week
Key Insights Significant control over Humacyte by individual investors implies that the general public has more power to influence management and governance-related decisions The top 25 shareholders
10-Q: Quarterly report
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Rallybio (RLYB)
Express News | Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 215.79% Benchmark → $15 Reiterates Buy → Buy 04/01/2024 47.37% Cantor Fitzgerald → $7 Reiterate
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
Comments
$HUMA - Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target.
One company that has been drawing significant attention from investors and analysts alike is Humacyte (HUMA). This pioneering firm, known for its innovative approaches in regenerative medicine, has once again found itself in the spotlight following a reaffirmation of confidence from the esteemed financial services firm, Benchmark Co. $Humacyte(HUMA.US$
https://stockregion.app/p/medical-company-receives-buy-rating
One company that has been drawing significant attention from investors and analysts alike is Humacyte (HUMA). This pioneering firm, known for its innovative approaches in regenerative medicine, has once again found itself in the spotlight following a reaffirmation of confidence from the esteemed financial services firm, Benchmark Co. $Humacyte(HUMA.US$
https://stockregion.app/p/medical-company-receives-buy-rating
$Humacyte(HUMA.US$ Senator Tommy Tuberville filed 8 security purchases, including small biotech company Humacyte (HUMA) which has been testing to repair injuries in Ukraine.
1
2
Read more